Live News EQUITY M impact Jun 25, 2026, 11:00 AM UTC

KYMR Completes Enrollment

Kymera Therapeutics completes enrollment in the Phase 2b BROADEN2 trial of KT-621 in atopic dermatitis with topline data expected by year-end 2026

SQUAWKNEWS Updated Jun 25, 2026, 11:00 AM UTC

KYMR - Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026